Literature DB >> 21671391

The Pitt-Hopkins syndrome: report of 16 new patients and clinical diagnostic criteria.

Giuseppe Marangi1, Stefania Ricciardi, Daniela Orteschi, Serena Lattante, Marina Murdolo, Bruno Dallapiccola, Chiara Biscione, Rosetta Lecce, Pietro Chiurazzi, Corrado Romano, Donatella Greco, Rosa Pettinato, Giovanni Sorge, Chiara Pantaleoni, Enrico Alfei, Irene Toldo, Cinzia Magnani, Paolo Bonanni, Federica Martinez, Gigliola Serra, Domenica Battaglia, Donatella Lettori, Gessica Vasco, Anna Baroncini, Cecilia Daolio, Marcella Zollino.   

Abstract

Pitt-Hopkins syndrome (PTHS) is characterized by severe intellectual disability, typical facial gestalt and additional features, such as breathing anomalies. Following the discovery of the causative haploinsufficiency of transcription factor 4 (TCF4), about 60 patients have been reported. We looked for TCF4 mutations in 63 patients with a suspected PTHS. Haploinsufficiency of TCF4 was identified in 14 patients, as a consequence of large 18q21.2 chromosome deletions involving TCF4 (2 patients), gene mutations (11 patients) and a t(14q;18q) balanced translocation disrupting TCF4 (one patient). By evaluating the clinical features of these patients, along with literature data, we noticed that, in addition to the typical facial gestalt, the PTHS phenotype results from the various combinations of the following characteristics: intellectual disability with severe speech impairment, normal growth parameters at birth, postnatal microcephaly, breathing anomalies, motor incoordination, ocular anomalies, constipation, seizures, typical behavior and subtle brain abnormalities. Although PTHS is currently considered to be involved in differential diagnosis with Angelman and Rett syndromes, we found that combining the facial characteristics with a detailed analysis of both the physical and the neurological phenotype, made molecular testing for PTHS the first choice. Based on striking clinical criteria, a diagnosis of PTHS was made clinically in two patients who had normal TCF4. This report deals with the first series of PTHS patients of Italian origin.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21671391     DOI: 10.1002/ajmg.a.34070

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  21 in total

1.  The CDKL5 disorder is an independent clinical entity associated with early-onset encephalopathy.

Authors:  Stephanie Fehr; Meredith Wilson; Jenny Downs; Simon Williams; Alessandra Murgia; Stefano Sartori; Marilena Vecchi; Gladys Ho; Roberta Polli; Stavroula Psoni; Xinhua Bao; Nick de Klerk; Helen Leonard; John Christodoulou
Journal:  Eur J Hum Genet       Date:  2012-08-08       Impact factor: 4.246

Review 2.  The Molecular Basis of Fuchs' Endothelial Corneal Dystrophy.

Authors:  Jie Zhang; Charles N J McGhee; Dipika V Patel
Journal:  Mol Diagn Ther       Date:  2019-02       Impact factor: 4.074

3.  Fuchs endothelial corneal dystrophy: a neurodegenerative disorder?

Authors:  Angela Y Zhu; Charles G Eberhart; Albert S Jun
Journal:  JAMA Ophthalmol       Date:  2014-04-01       Impact factor: 7.389

Review 4.  Clinical review of genetic epileptic encephalopathies.

Authors:  Grace J Noh; Y Jane Tavyev Asher; John M Graham
Journal:  Eur J Med Genet       Date:  2012-01-25       Impact factor: 2.708

5.  Pitt-Hopkins Syndrome.

Authors:  M Peippo; J Ignatius
Journal:  Mol Syndromol       Date:  2011-12-29

6.  Mutations in epilepsy and intellectual disability genes in patients with features of Rett syndrome.

Authors:  Heather E Olson; Dimira Tambunan; Christopher LaCoursiere; Marti Goldenberg; Rebecca Pinsky; Emilie Martin; Eugenia Ho; Omar Khwaja; Walter E Kaufmann; Annapurna Poduri
Journal:  Am J Med Genet A       Date:  2015-04-25       Impact factor: 2.802

7.  Disruption of MBD5 contributes to a spectrum of psychopathology and neurodevelopmental abnormalities.

Authors:  J C Hodge; E Mitchell; V Pillalamarri; T L Toler; F Bartel; H M Kearney; Y S Zou; W H Tan; C Hanscom; S Kirmani; R R Hanson; S A Skinner; R C Rogers; D B Everman; E Boyd; C Tapp; S V Mullegama; D Keelean-Fuller; C M Powell; S H Elsea; C C Morton; J F Gusella; B DuPont; A Chaubey; A E Lin; M E Talkowski
Journal:  Mol Psychiatry       Date:  2013-04-16       Impact factor: 15.992

Review 8.  Pitt-Hopkins Syndrome and Differential Diagnosis: A Molecular and Clinical Challenge.

Authors:  Giuseppe Marangi; Marcella Zollino
Journal:  J Pediatr Genet       Date:  2015-09-25

9.  Molecular Mechanisms of Transcription Factor 4 in Pitt Hopkins Syndrome.

Authors:  Matthew D Rannals; Brady J Maher
Journal:  Curr Genet Med Rep       Date:  2017-02-11

10.  Common variants at VRK2 and TCF4 conferring risk of schizophrenia.

Authors:  Stacy Steinberg; Simone de Jong; Ole A Andreassen; Thomas Werge; Anders D Børglum; Ole Mors; Preben B Mortensen; Omar Gustafsson; Javier Costas; Olli P H Pietiläinen; Ditte Demontis; Sergi Papiol; Johanna Huttenlocher; Manuel Mattheisen; René Breuer; Evangelos Vassos; Ina Giegling; Gillian Fraser; Nicholas Walker; Annamari Tuulio-Henriksson; Jaana Suvisaari; Jouko Lönnqvist; Tiina Paunio; Ingrid Agartz; Ingrid Melle; Srdjan Djurovic; Eric Strengman; Gesche Jürgens; Birte Glenthøj; Lars Terenius; David M Hougaard; Torben Ørntoft; Carsten Wiuf; Michael Didriksen; Mads V Hollegaard; Merete Nordentoft; Ruud van Winkel; Gunter Kenis; Lilia Abramova; Vasily Kaleda; Manuel Arrojo; Julio Sanjuán; Celso Arango; Swetlana Sperling; Moritz Rossner; Michele Ribolsi; Valentina Magni; Alberto Siracusano; Claus Christiansen; Lambertus A Kiemeney; Jan Veldink; Leonard van den Berg; Andres Ingason; Pierandrea Muglia; Robin Murray; Markus M Nöthen; Engilbert Sigurdsson; Hannes Petursson; Unnur Thorsteinsdottir; Augustine Kong; I Alex Rubino; Marc De Hert; János M Réthelyi; István Bitter; Erik G Jönsson; Vera Golimbet; Angel Carracedo; Hannelore Ehrenreich; Nick Craddock; Michael J Owen; Michael C O'Donovan; Mirella Ruggeri; Sarah Tosato; Leena Peltonen; Roel A Ophoff; David A Collier; David St Clair; Marcella Rietschel; Sven Cichon; Hreinn Stefansson; Dan Rujescu; Kari Stefansson
Journal:  Hum Mol Genet       Date:  2011-07-26       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.